- MEDIAN Technologies will present results of a study: “Identification of measurable lesions: an opportunity for improving reliability of RECIST assessments”;
- MEDIAN Technologies co-authored an oral presentation done by the Saga University, Japan: “RECIST management at investigator sites: evaluation of a cloud-based quality control of imaging evaluations in clinical trials”;
- MEDIAN Technologies co-authored a poster publication done by the University Hospital of Nice, France: “Cloud-based quality control for volume-based response assessment in clinical trials: a pilot study”
MEDIAN Technologies, a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, has announced it will present the results of three studies at the European Radiology Congress (ECR), held March 6-10, in Vienna, Austria.
The ECR is the premier radiology conference in Europe and is organised by the European Society of Radiology (ESR).
“Identification of measurable lesions: an opportunity for improving reliability of RECIST assessments”:
Response Evaluation Criteria in Solid Tumor (RECIST) is the main imaging criteria in oncology. Several limitations have however been documented, one of them consisting in the identification and management of “Measurable” Lesions (ML). In its will to improve RECIST-based patient monitoring, MEDIAN investigated new methods to help the selection of the most evaluable pulmonary lesions through thoracic CT scans. The study demonstrated that the management of measurable / non measurable lesions may affect the quality of diagnosis, and that visually discriminating which are the most reliable lesions is difficult for readers. However, the study demonstrated that identifying and selecting measurable lesions in a reliable way is achievable and can be dramatically improved using computer aided systems. The poster of the study is available on the ECR website
“RECIST management at investigator sites: evaluation of a cloud-based quality control of imaging evaluations in clinical trials”:
Imaging evaluations for clinical trials in oncology request as far as possible a standardised application of criteria used to assess response to treatment. The study dealt with the setup and evaluation of a cloud-based quality control of imaging evaluations done at investigator sites, with the objective to standardise the application of RECIST (Response Evaluation Criteria in Solid Tumors) criteria. For the purpose of the study, MEDIAN solutions were deployed at investigator sites in Japan, France and Scotland, and all images and evaluation data were stored in a Japan-based data center. The study demonstrated both the feasibility and the benefits of a cloud implementation in the context of international multi-center studies. The quality control provided a strict compliance to RECIST criteria for all evaluations and improved the inter-reader agreement regarding the choice of target lesions.
“Cloud-based quality control for volume-based response assessment in clinical trials: a pilot study”:
Tumor volume may address some of the RECIST (Response Evaluation Criteria in Solid Tumors) limitations that jeopardise the consistency of imaging assessments in oncology trials. The study evaluated some investigational volume-based criteria, in the frame of a cloud implementation of MEDIAN solutions, with the objective to standardise response evaluations among investigators. The study compared volume-based criteria to RECIST regarding inter-reader agreement and evaluated the impact of a cloud-based quality control for establishing a consensus on the choice of target lesions and new lesions. The study showed that, unlike RECIST, volume-based criteria improve response agreement among readers when a consensus on target lesions is performed. The study also demonstrated the positive impact of a consensus about new lesions on response evaluation agreement. The poster of the study is available on the ECR website.
6 March 2014